HanmiScience Q1 Sales 320.2 Billion KRW... Operating Profit Up 19%

Hanmi Science, the holding company of Hanmi Pharmaceutical Group, announced on the 3rd that it recorded provisional consolidated financial results for the first quarter of this year with sales of 320.152 billion KRW and an operating profit of 37.33 billion KRW. Compared to the same period last year, sales grew by 9.9% and operating profit increased by 19.0%. A Hanmi Science representative stated, “We achieved strong performance supported by balanced growth across each core affiliate and results in the healthcare business sector.”

Hanmi Pharmaceutical Headquarters Exterior [Photo by Hanmi Pharmaceutical]

The core affiliate Hanmi Pharmaceutical posted sales of 403.684 billion KRW in the first quarter of this year, an 11.8% increase compared to the same period last year, while Beijing Hanmi Pharmaceutical, its local subsidiary in China, recorded quarterly sales of 127.7 billion KRW, surpassing 100 billion KRW. JVM, a specialist company in pharmaceutical automation systems, also achieved solid results by exceeding sales of 40 billion KRW. The healthcare business sector posted sales of 30.6 billion KRW, a 10.1% increase year-on-year, and Online Pharm, a subsidiary in the pharmaceutical wholesale sector, reported sales of 272.3 billion KRW.

A Hanmi Science representative said, “The first quarter was a period that presented the direction Hanmi Science should take as a ‘business-type holding company’ with its own sales,” adding, “We will do our best to broadly present the potential for innovation that can lead the rapidly changing global healthcare market to the market, thereby further enhancing corporate value and shareholder value.”